According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Other equities analysts have also recently issued research reports about the stock. Royal Bank Of Canada reaffirmed an outperform rating and issued a $23.00 price objective on shares of Aptose Biosciences in a research note on Monday, June 13th. RBC Capital Markets reaffirmed an outperform rating on shares of Aptose Biosciences in a research note on Tuesday, September 13th. Finally, Roth Capital raised shares of Aptose Biosciences from a neutral rating to a buy rating and lifted their price objective for the stock from $4.00 to $8.00 in a research note on Monday, June 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Aptose Biosciences currently has a consensus rating of Buy and an average price target of $12.30.
Aptose Biosciences (NASDAQ:APTO) opened at 2.411 on Tuesday. Aptose Biosciences has a 52 week low of $1.92 and a 52 week high of $6.40. The stock’s market cap is $31.08 million. The company’s 50 day moving average is $2.21 and its 200 day moving average is $2.47.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors own 19.47% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.